Related Experiment Video
Updated: Apr 4, 2026
Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
Low-dose Exogenous Ouabain Alleviates Cardiac Lipotoxicity Through Suppressing Expression of CD36
Ning Guo1, Wenting Ai, Xin Jiang
1Department of Cardiology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Abstract:
CD36 is a key transporter involved in fatty acid (FA) uptake and contributes to the accumulation of FA in cardiomyocytes. The objective of this study was to investigate the role of ouabain, a glycoside regulator of Na(+)/K(+)-ATPase, in the regulation of CD36 expression and FA accumulation. FATP1 transgenic (Tg) mice with lipotoxic cardiomyopathy displayed significantly increased cardiac CD36 expression and free fatty acid accumulation. The data on enzyme-linked immunosorbent assay showed that endogenous ouabain was decreased in the serum of Tg mice versus wild-type mice. CD36 expression and free fatty acid accumulation in their primary cardiomyocytes were abated by treatment with 0.15-0.30 μM ouabain. CD36 expression was suppressed by 0.2 μM ouabain treatment, and the suppression was rescued by C-reactive protein. CD36 expression and free fatty acid accumulation in the heart were markedly reduced in Tg mice injected with 30 or 40 ng of ouabain (P < 0.01). Obvious fatty infiltration was found in noninjected Tg mice but not in the mice injected with 40 ng of ouabain. In conclusion, low-dose exogenous ouabain increased Na(+)/K(+)-ATPase activity, suppressed C-reactive protein-mediated CD36 expression, and alleviated murine cardiac lipotoxicity in vitro and in vivo.
Insights
Low-dose ouabain treatment reduced fatty acid accumulation in heart cells by decreasing CD36 transporter expression. This finding offers a potential therapeutic strategy for lipotoxic cardiomyopathy.
Area of Science:
- Cardiology
- Molecular Biology
- Biochemistry
Background:
- CD36 is crucial for fatty acid (FA) uptake and accumulation in cardiomyocytes, contributing to lipotoxic cardiomyopathy.
- Na(+)/K(+)-ATPase regulator ouabain's role in CD36 expression and FA accumulation is not fully understood.
Purpose of the Study:
- To investigate the effect of ouabain on CD36 expression and FA accumulation in the context of lipotoxic cardiomyopathy.
- To determine if ouabain can alleviate cardiac lipotoxicity.
Main Methods:
- Utilized FATP1 transgenic (Tg) mice with lipotoxic cardiomyopathy.
- Measured cardiac CD36 expression and free fatty acid (FA) accumulation.
- Assessed the impact of varying ouabain concentrations on primary cardiomyocytes and Tg mice.
- Investigated the role of C-reactive protein in ouabain's effect on CD36 expression.
Main Results:
- Tg mice showed increased cardiac CD36 expression and FA accumulation, with decreased endogenous ouabain.
- Low-dose ouabain (0.15-0.30 μM) treatment reduced CD36 expression and FA accumulation in cardiomyocytes.
- Ouabain suppressed CD36 expression, an effect that was reversed by C-reactive protein.
- In vivo ouabain administration significantly reduced cardiac CD36 expression, FA accumulation, and fatty infiltration in Tg mice.
Conclusions:
- Low-dose exogenous ouabain enhances Na(+)/K(+)-ATPase activity.
- Ouabain suppresses C-reactive protein-mediated CD36 expression.
- Ouabain alleviates cardiac lipotoxicity in vitro and in vivo, suggesting therapeutic potential.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Atherosclerosis III: Management